Akari Therapeutics (AKTX) Asset Writedowns and Impairment (2025 - 2026)
Akari Therapeutics (AKTX) posted quarterly Asset Writedowns and Impairment of $3.7 million for Q1 2026, down 28.57% on a QoQ basis from $5.2 million in Q3 2025.
Akari Therapeutics (AKTX) Asset Writedowns and Impairment (2025 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Asset Writedowns and Impairment for 2 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.70 Mn |
| Mar 31, 2026 | 3.70 Mn |
| Sep 30, 2025 | 5.18 Mn |
| Sep 30, 2025 | 5.18 Mn |